Open AccessRibociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR +/ HER2 – Advanced Breast Cancer
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13866
Subject(s) - medicine , fulvestrant , oncology , postmenopausal women , breast cancer , cancer , overall survival , gynecology , tamoxifen
In an updated analysis from the phase III MONALEESA‐3 trial with more than 4.5 years of follow‐up, ribociclib plus fulvestrant maintained a significant overall survival benefit compared with fulvestrant alone in postmenopausal women with HR‐negative, HER2‐positive advanced breast cancer.